A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.

@article{Butler2007API,
  title={A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.},
  author={Jerome M Butler and Larry Douglas Case and James Blake Atkins and B. S. Frizzell and George Sanders and Patricia C. Griffin and Glenn Jay Lesser and Kevin Patrick Mcmullen and Richard P. McQuellon and Michelle M Naughton and Stephen Rapp and Volker W. Stieber and Edward G. Shaw},
  journal={International journal of radiation oncology, biology, physics},
  year={2007},
  volume={69 5},
  pages={1496-501}
}
PURPOSE The quality of life (QOL) and neurocognitive function of patients with brain tumors are negatively affected by the symptoms of their disease and brain radiation therapy (RT). We assessed the effect of prophylactic d-threo-methylphenidate HCl (d-MPH), a central nervous system (CNS) stimulant on QOL and cognitive function in patients undergoing RT. METHODS AND MATERIALS Sixty-eight patients with primary or metastatic brain tumors were randomly assigned to receive d-MPH or placebo. The… CONTINUE READING